Global Longevity and Anti-senescence Therapy Market
REPORT SCOPE:
The scope of this report is broad and covers various therapies currently under trials in the global longevity and anti-senescence therapy market. The market estimation has been performed with consideration for revenue generation in the forecast years 2018-2023 after the expected availability of products in the market by 2023. The global longevity and anti-senescence therapy market has been segmented by the following therapies: Senolytic drug therapy, Gene therapy, Immunotherapy and Other therapies which includes stem cell-based therapies, etc.
Revenue forecasts from 2028 to 2023 are given for each therapy and application, with estimated values derived from the expected revenue generation in the first year of launch.
The report also includes a discussion of the major players performing research or the potential players across each regional longevity and anti-senescence therapy market. Further, it explains the major drivers and regional dynamics of the global longevity and anti-senescence therapy market and current trends within the industry.
The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors and potential entrants in the global longevity and anti-senescence therapy market.
REPORT INCLUDES:
The scope of this report is broad and covers various therapies currently under trials in the global longevity and anti-senescence therapy market. The market estimation has been performed with consideration for revenue generation in the forecast years 2018-2023 after the expected availability of products in the market by 2023. The global longevity and anti-senescence therapy market has been segmented by the following therapies: Senolytic drug therapy, Gene therapy, Immunotherapy and Other therapies which includes stem cell-based therapies, etc.
Revenue forecasts from 2028 to 2023 are given for each therapy and application, with estimated values derived from the expected revenue generation in the first year of launch.
The report also includes a discussion of the major players performing research or the potential players across each regional longevity and anti-senescence therapy market. Further, it explains the major drivers and regional dynamics of the global longevity and anti-senescence therapy market and current trends within the industry.
The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors and potential entrants in the global longevity and anti-senescence therapy market.
REPORT INCLUDES:
- 71 data tables and 40 additional tables
- An overview of the global longevity and anti-senescence therapy market
- Analyses of global market trends, with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Country specific data and analysis for the United States, Canada, Japan, China, India, U.K., France, Germany, Spain, Australia, Middle East and Africa
- Detailed description of various anti-senescence therapies, such as senolytic drug therapy, gene therapy, immunotherapy and other stem cell therapies, and their influence in slowing down aging or reverse aging process
- Coverage of various therapeutic drugs, devices and technologies and information on compounds used for the development of anti-ageing therapeutics
- A look at the clinical trials and expected launch of anti-senescence products
- Detailed profiles of the market leading companies and potential entrants in the global longevity and anti-senescence therapy market, including AgeX Therapeutics, CohBar Inc., PowerVision Inc., T.A. Sciences and Unity Biotechnology
CHAPTER 1 INTRODUCTION
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET OVERVIEW
Introduction
Drugs, Devices and Technologies Used in the Longevity and Anti-senescence Market
Market Evolution and Key Future Trends
Timeline of Longevity and Anti-senescence
Key Future Trends
Clinical Trials and the Expected Launch of Anti-senescence Products
Standards and Regulations in the Market
United States
European Union
Japan
India
Brazil
Industry Growth Drivers
Increasing Geriatric Population Across the Globe
Surging Level of Disposable Income
Rising Awareness of Anti-Aging Products Among Generation Y and Later Generations
Increasing Advancements in Anti-senescence Technologies
CHAPTER 4 GLOBAL LONGEVITY AND ANTI-SENESCENCE MARKET BY THERAPY
Senolytic Drug Therapy
Gene Therapy
Immunotherapy
Others
CHAPTER 5 GLOBAL LONGEVITY AND ANTI-SENESCENCE MARKET BY APPLICATION
Longevity
Senescence Inhibition
Cardiovascular Diseases
Neural Degenerative Diseases
Ophthalmology Disorders
Cancer
CHAPTER 6 GLOBAL LONGEVITY AND ANTI-SENESCENCE MARKET BY REGION
North America
United States
Canada
Europe
United Kingdom
France
Germany
Spain
Rest of Europe
Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
Rest of World
Latin America
Middle East and Africa
CHAPTER 7 INDUSTRY STRUCTURE IN LONGEVITY AND ANTI-SENESCENCE MARKET
Industry Structure
Suppliers
Research and Development
Manufacturing/Production
Distribution and Marketing
End Users
Investments and Funding Analysis
CHAPTER 8 COMPANY PROFILES
ACORDA THERAPEUTICS
AGEX THERAPEUTICS
ANTOXERENE
CALICO LIFE SCIENCES
CELGENE
CLEARA BIOTECH
COHBAR
HUMAN LONGEVITY INC.
INSILICO MEDICINE
OISIN BIOTECHNOLOGY
POWERVISION INC.
PRANA BIOTECHNOLOGY LTD.
PROTEOSTASIS THERAPEUTICS INC.
RECURSION PHARMACEUTICALS
RESTORBIO
SIERRA SCIENCES LLC
SENEX BIOTECHNOLOGY
SENOLYTIC THERAPEUTICS
SPOTLIGHT BIOSCIENCE
T.A. SCIENCES
UNITY BIOTECHNOLOGY
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET OVERVIEW
Introduction
Drugs, Devices and Technologies Used in the Longevity and Anti-senescence Market
Market Evolution and Key Future Trends
Timeline of Longevity and Anti-senescence
Key Future Trends
Clinical Trials and the Expected Launch of Anti-senescence Products
Standards and Regulations in the Market
United States
European Union
Japan
India
Brazil
Industry Growth Drivers
Increasing Geriatric Population Across the Globe
Surging Level of Disposable Income
Rising Awareness of Anti-Aging Products Among Generation Y and Later Generations
Increasing Advancements in Anti-senescence Technologies
CHAPTER 4 GLOBAL LONGEVITY AND ANTI-SENESCENCE MARKET BY THERAPY
Senolytic Drug Therapy
Gene Therapy
Immunotherapy
Others
CHAPTER 5 GLOBAL LONGEVITY AND ANTI-SENESCENCE MARKET BY APPLICATION
Longevity
Senescence Inhibition
Cardiovascular Diseases
Neural Degenerative Diseases
Ophthalmology Disorders
Cancer
CHAPTER 6 GLOBAL LONGEVITY AND ANTI-SENESCENCE MARKET BY REGION
North America
United States
Canada
Europe
United Kingdom
France
Germany
Spain
Rest of Europe
Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
Rest of World
Latin America
Middle East and Africa
CHAPTER 7 INDUSTRY STRUCTURE IN LONGEVITY AND ANTI-SENESCENCE MARKET
Industry Structure
Suppliers
Research and Development
Manufacturing/Production
Distribution and Marketing
End Users
Investments and Funding Analysis
CHAPTER 8 COMPANY PROFILES
ACORDA THERAPEUTICS
AGEX THERAPEUTICS
ANTOXERENE
CALICO LIFE SCIENCES
CELGENE
CLEARA BIOTECH
COHBAR
HUMAN LONGEVITY INC.
INSILICO MEDICINE
OISIN BIOTECHNOLOGY
POWERVISION INC.
PRANA BIOTECHNOLOGY LTD.
PROTEOSTASIS THERAPEUTICS INC.
RECURSION PHARMACEUTICALS
RESTORBIO
SIERRA SCIENCES LLC
SENEX BIOTECHNOLOGY
SENOLYTIC THERAPEUTICS
SPOTLIGHT BIOSCIENCE
T.A. SCIENCES
UNITY BIOTECHNOLOGY
LIST OF TABLES
Summary Table: Global Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 1: Various Approaches to Anti-aging Therapeutics
Table 2: Increasing Global Life Expectancy (in Years) for Both Sexes, by Region, 2000-2016
Table 3: Drugs and Biologics Related to Aging Under Various Phases of Clinical Trials, as of January 2019
Table 4: Global Population Aged 60 Years and Older, by Region, 2015, 2030 and 2050
Table 5: Global Geriatric Population (Aged 65 Years and Older), 2014-2022
Table 6: Percentage Distribution of Worldwide Population (Aged 65 Years and Older), by Region, 2016 and 2050
Table 7: Household Disposable Income Across Selected Countries, 2012-2018
Table 8: Lifetime UV Exposure in the United States
Table 9: Start-up Companies in Anti-Aging Solutions
Table 10: Global Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 11: Types of Senolytics Drugs
Table 12: Global Market for Senolytic Drug Therapy, by Region, Through 2023
Table 13: Population Aged 65 Years and Older, 2012-2017
Table 14: Global Market for Gene Therapy, by Region, Through 2023
Table 15: Leading Institutional Developers of Genomics Tools, 2017
Table 16: Global Market for Immunotherapy, by Region, Through 2023
Table 17: Global Market for Other Therapies, by Region, Through 2023
Table 18: Global Market for Longevity and Anti-senescence in Drug Discovery and Development, by Region, Through 2023
Table 19: Global Market for Longevity and Anti-senescence in Senescence Inhibition, by Region, Through 2023
Table 20: Global Market for Longevity and Anti-senescence in Cardiovascular Diseases, by Region, Through 2023
Table 21: Number of People with Dementia Worldwide, by Income Level, 2015-2050
Table 22: Investments in Alzheimer’s Disease Treatment
Table 23: Global Market for Longevity and Anti-senescence in Neural Degenerative Diseases, by Region, Through 2023
Table 24: Global Market for Longevity and Anti-senescence in Ophthalmology Disorders, by Region, Through 2023
Table 25: Global Number of Adults with Diabetes, 2015 and 2040
Table 26: Top 10 Countries with the Highest Prevalence of Diabetes, 2015
Table 27: Percentage Increment of Diabetes Across Regions, 2015-2040
Table 28: Global Market for Longevity and Anti-senescence in Cancer, by Region, Through 2023
Table 29: Global Cancer Prevalence, by Type, 2016
Table 30: Cancer Prevalence Across Regions, by Type, 2015-2016
Table 31: North American Number and Distribution of Persons Aged 60 Years or Older, 2017 and 2050
Table 32: Demographic Indicators Related to Population Aging in North America, by Country, 2017 and 2050
Table 33: North American Market for Longevity and Anti-senescence, by Country, Through 2023
Table 34: North American Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 35: North American Market for Longevity and Anti-senescence, by Application, Through 2023
Table 36: United States’ Market for Longevity and Anti-senescence, by Application, Through 2023
Table 37: United States’ Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 38: Canadian Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 39: Canadian Market for Longevity and Anti-senescence, by Application, Through 2023
Table 40: European Market for Longevity and Anti-senescence, by Country, Through 2023
Table 41: European Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 42: European Market for Longevity and Anti-senescence, by Application, Through 2023
Table 43: U.K. Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 44: UK Market for Longevity and Anti-senescence, by Application, Through 2023
Table 45: French Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 46: French Market for Longevity and Anti-senescence, by Application, Through 2023
Table 47: German Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 48: German Market for Longevity and Anti-senescence, by Application, Through 2023
Table 49: Spanish Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 50: Spanish Market for Longevity and Anti-senescence, by Application, Through 2023
Table 51: Rest of the European Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 52: Rest of the European Market for Longevity and Anti-senescence, by Application, Through 2023
Table 53: Asia-Pacific Market for Longevity and Anti-senescence, by Country, Through 2023
Table 54: Asia-Pacific Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 55: Asia-Pacific Market for Longevity and Anti-senescence, by Application, Through 2023
Table 56: Chinese Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 57: Chinese Market for Longevity and Anti-senescence, by Application, Through 2023
Table 58: Total Rural Income in India, 2015 and 2021
Table 59: Indian Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 60: Indian Market for Longevity and Anti-senescence, by Application, Through 2023
Table 61: Share of Population Aged 65 Years and Older in Japan, 2015 and 2050
Table 62: Japanese Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 63: Japanese Market for Longevity and Anti-senescence, by Application, Through 2023
Table 64: Share of Australian Population Aged 60 Years and Older, 2015 and 2050
Table 65: Australian Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 66: Australian Market for Longevity and Anti-senescence, by Application, Through 2023
Table 67: Rest of APAC Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 68: Rest of APAC Market for Longevity and Anti-senescence, by Application, Through 2023
Table 69: RoW Market for Longevity and Anti-senescence, by Region, Through 2023
Table 70: RoW Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 71: RoW Market for Longevity and Anti-senescence, by Application, Through 2023
Table 72: Latin American Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 73: Latin American Market for Longevity and Anti-senescence, by Application, Through 2023
Table 74: Disposable Income in UAE, 2010 and 2017
Table 75: Middle Eastern and African Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 76: Middle Eastern and African Market for Longevity and Anti-senescence, by Application, Through 2023
Table 77: Global Suppliers to Longevity and Anti-senescence Market
Table 78: Some of the Notable Longevity and Anti-senescence Companies
Table 79: Investment Analysis: Longevity and Anti-senescence Therapy Market
Table 80: Product Portfolio: Acorda Therapeutics
Table 81: Product Portfolio: AgeX Therapeutics
Table 82: Recent Developments: AgeX Therapeutics, 2016-2018
Table 83: Product Portfolio: Antoxerene
Table 84: Recent Developments: Antoxerene, 2016-2018
Table 85: Recent Developments: Calico Life Sciences, 2016-2018
Table 86: Product Portfolio: Celgene
Table 87: Product Portfolio: Cleara Biotech
Table 88: Recent Developments: Cleara Biotech, 2016-2018
Table 89: Product Portfolio: CohBar
Table 90: Recent Developments: CohBar, 2016-2018
Table 91: Product Portfolio: Human Longevity Inc.
Table 92: Recent Developments: Human Longevity Inc., 2016-2018
Table 93: Product Portfolio: Insilico Medicine
Table 94: Recent Developments: Insilico Medicine, 2016-2018
Table 95: Product Portfolio: Oisin Biotechnology
Table 96: Product Portfolio: PowerVision Inc.
Table 97: Recent Developments: PowerVision Inc., 2016-2018
Table 98: Product Portfolio: Prana Biotechnology Ltd.
Table 99: Recent Developments: Prana Biotechnology Ltd., 2016-2018
Table 100: Product Portfolio: Proteostasis Therapeutics Inc.
Table 101: Product Portfolio: Recursion Pharmaceuticals
Table 102: Recent Developments: Recursion Pharmaceuticals, 2016-2018
Table 103: Product Portfolio: resTORbio
Table 104: Product Portfolio (Pipeline): Senex Biotechnology
Table 105: Product Portfolio: Senolytic Therapeutics
Table 106: Product Portfolio: Spotlight Bioscience
Table 107: Product Portfolio: T.A. Sciences
Table 108: Recent Developments: T.A. Sciences, 2016-2018
Table 109: Product Portfolio: Unity Biotechnology
Table 110: Recent Developments: Unity Biotechnology, 2017-2019
Summary Table: Global Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 1: Various Approaches to Anti-aging Therapeutics
Table 2: Increasing Global Life Expectancy (in Years) for Both Sexes, by Region, 2000-2016
Table 3: Drugs and Biologics Related to Aging Under Various Phases of Clinical Trials, as of January 2019
Table 4: Global Population Aged 60 Years and Older, by Region, 2015, 2030 and 2050
Table 5: Global Geriatric Population (Aged 65 Years and Older), 2014-2022
Table 6: Percentage Distribution of Worldwide Population (Aged 65 Years and Older), by Region, 2016 and 2050
Table 7: Household Disposable Income Across Selected Countries, 2012-2018
Table 8: Lifetime UV Exposure in the United States
Table 9: Start-up Companies in Anti-Aging Solutions
Table 10: Global Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 11: Types of Senolytics Drugs
Table 12: Global Market for Senolytic Drug Therapy, by Region, Through 2023
Table 13: Population Aged 65 Years and Older, 2012-2017
Table 14: Global Market for Gene Therapy, by Region, Through 2023
Table 15: Leading Institutional Developers of Genomics Tools, 2017
Table 16: Global Market for Immunotherapy, by Region, Through 2023
Table 17: Global Market for Other Therapies, by Region, Through 2023
Table 18: Global Market for Longevity and Anti-senescence in Drug Discovery and Development, by Region, Through 2023
Table 19: Global Market for Longevity and Anti-senescence in Senescence Inhibition, by Region, Through 2023
Table 20: Global Market for Longevity and Anti-senescence in Cardiovascular Diseases, by Region, Through 2023
Table 21: Number of People with Dementia Worldwide, by Income Level, 2015-2050
Table 22: Investments in Alzheimer’s Disease Treatment
Table 23: Global Market for Longevity and Anti-senescence in Neural Degenerative Diseases, by Region, Through 2023
Table 24: Global Market for Longevity and Anti-senescence in Ophthalmology Disorders, by Region, Through 2023
Table 25: Global Number of Adults with Diabetes, 2015 and 2040
Table 26: Top 10 Countries with the Highest Prevalence of Diabetes, 2015
Table 27: Percentage Increment of Diabetes Across Regions, 2015-2040
Table 28: Global Market for Longevity and Anti-senescence in Cancer, by Region, Through 2023
Table 29: Global Cancer Prevalence, by Type, 2016
Table 30: Cancer Prevalence Across Regions, by Type, 2015-2016
Table 31: North American Number and Distribution of Persons Aged 60 Years or Older, 2017 and 2050
Table 32: Demographic Indicators Related to Population Aging in North America, by Country, 2017 and 2050
Table 33: North American Market for Longevity and Anti-senescence, by Country, Through 2023
Table 34: North American Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 35: North American Market for Longevity and Anti-senescence, by Application, Through 2023
Table 36: United States’ Market for Longevity and Anti-senescence, by Application, Through 2023
Table 37: United States’ Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 38: Canadian Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 39: Canadian Market for Longevity and Anti-senescence, by Application, Through 2023
Table 40: European Market for Longevity and Anti-senescence, by Country, Through 2023
Table 41: European Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 42: European Market for Longevity and Anti-senescence, by Application, Through 2023
Table 43: U.K. Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 44: UK Market for Longevity and Anti-senescence, by Application, Through 2023
Table 45: French Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 46: French Market for Longevity and Anti-senescence, by Application, Through 2023
Table 47: German Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 48: German Market for Longevity and Anti-senescence, by Application, Through 2023
Table 49: Spanish Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 50: Spanish Market for Longevity and Anti-senescence, by Application, Through 2023
Table 51: Rest of the European Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 52: Rest of the European Market for Longevity and Anti-senescence, by Application, Through 2023
Table 53: Asia-Pacific Market for Longevity and Anti-senescence, by Country, Through 2023
Table 54: Asia-Pacific Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 55: Asia-Pacific Market for Longevity and Anti-senescence, by Application, Through 2023
Table 56: Chinese Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 57: Chinese Market for Longevity and Anti-senescence, by Application, Through 2023
Table 58: Total Rural Income in India, 2015 and 2021
Table 59: Indian Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 60: Indian Market for Longevity and Anti-senescence, by Application, Through 2023
Table 61: Share of Population Aged 65 Years and Older in Japan, 2015 and 2050
Table 62: Japanese Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 63: Japanese Market for Longevity and Anti-senescence, by Application, Through 2023
Table 64: Share of Australian Population Aged 60 Years and Older, 2015 and 2050
Table 65: Australian Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 66: Australian Market for Longevity and Anti-senescence, by Application, Through 2023
Table 67: Rest of APAC Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 68: Rest of APAC Market for Longevity and Anti-senescence, by Application, Through 2023
Table 69: RoW Market for Longevity and Anti-senescence, by Region, Through 2023
Table 70: RoW Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 71: RoW Market for Longevity and Anti-senescence, by Application, Through 2023
Table 72: Latin American Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 73: Latin American Market for Longevity and Anti-senescence, by Application, Through 2023
Table 74: Disposable Income in UAE, 2010 and 2017
Table 75: Middle Eastern and African Market for Longevity and Anti-senescence, by Therapy, Through 2023
Table 76: Middle Eastern and African Market for Longevity and Anti-senescence, by Application, Through 2023
Table 77: Global Suppliers to Longevity and Anti-senescence Market
Table 78: Some of the Notable Longevity and Anti-senescence Companies
Table 79: Investment Analysis: Longevity and Anti-senescence Therapy Market
Table 80: Product Portfolio: Acorda Therapeutics
Table 81: Product Portfolio: AgeX Therapeutics
Table 82: Recent Developments: AgeX Therapeutics, 2016-2018
Table 83: Product Portfolio: Antoxerene
Table 84: Recent Developments: Antoxerene, 2016-2018
Table 85: Recent Developments: Calico Life Sciences, 2016-2018
Table 86: Product Portfolio: Celgene
Table 87: Product Portfolio: Cleara Biotech
Table 88: Recent Developments: Cleara Biotech, 2016-2018
Table 89: Product Portfolio: CohBar
Table 90: Recent Developments: CohBar, 2016-2018
Table 91: Product Portfolio: Human Longevity Inc.
Table 92: Recent Developments: Human Longevity Inc., 2016-2018
Table 93: Product Portfolio: Insilico Medicine
Table 94: Recent Developments: Insilico Medicine, 2016-2018
Table 95: Product Portfolio: Oisin Biotechnology
Table 96: Product Portfolio: PowerVision Inc.
Table 97: Recent Developments: PowerVision Inc., 2016-2018
Table 98: Product Portfolio: Prana Biotechnology Ltd.
Table 99: Recent Developments: Prana Biotechnology Ltd., 2016-2018
Table 100: Product Portfolio: Proteostasis Therapeutics Inc.
Table 101: Product Portfolio: Recursion Pharmaceuticals
Table 102: Recent Developments: Recursion Pharmaceuticals, 2016-2018
Table 103: Product Portfolio: resTORbio
Table 104: Product Portfolio (Pipeline): Senex Biotechnology
Table 105: Product Portfolio: Senolytic Therapeutics
Table 106: Product Portfolio: Spotlight Bioscience
Table 107: Product Portfolio: T.A. Sciences
Table 108: Recent Developments: T.A. Sciences, 2016-2018
Table 109: Product Portfolio: Unity Biotechnology
Table 110: Recent Developments: Unity Biotechnology, 2017-2019
LIST OF FIGURES
Summary Figure: Global Market for Longevity and Anti-senescence, by Therapy, 2017-2023
Figure 1: Increasing Global Life Expectancy (in Years) for Both Sexes, by Region, 2000-2016
Figure 2: Global Geriatric Population (Aged 65 Years and Older), 2014-2022
Figure 3: Percentage Distribution of Worldwide Population (Aged 65 Years and Older), by Region, 2016 and 2050
Figure 4: Household Disposable Income Across Selected Countries, 2012-2018
Figure 5: Population Aged 65 Years and Older, 2012-2017
Figure 6: Number of People with Dementia Worldwide, by Income Level, 2015-2050
Figure 7: Global Number of Adults with Diabetes, 2015 and 2040
Figure 8: Top 10 Countries with the Highest Prevalence of Diabetes, 2015
Figure 9: Percentage Distribution of Increasing Diabetes Cases, by Region, 2015-2040
Figure 10: Global Cancer Prevalence, by Type, 2016
Figure 11: Cancer Prevalence Across Regions, by Type, 2015-2016
Figure 12: Canadian Population Shares Distribution, by Province or Territory, 2018
Figure 13: Index of Mean and Median Equivalized Household Disposable Income in the U.K., 2015-2017
Figure 14: Geriatric Population in France, 2012 and 2017
Figure 15: Total Rural Income in India, 2015 and 2021
Figure 16: Share of Japanese Population Aged 65 Years and Older, 2015 and 2050
Figure 17: Share of Australian Population Aged 60 Years and Older, 2015 and 2050
Figure 18: Disposable Income in UAE, 2010 and 2017
Figure 19: Industry Structure and Process Flow: Longevity and Anti-senescence Industry
Summary Figure: Global Market for Longevity and Anti-senescence, by Therapy, 2017-2023
Figure 1: Increasing Global Life Expectancy (in Years) for Both Sexes, by Region, 2000-2016
Figure 2: Global Geriatric Population (Aged 65 Years and Older), 2014-2022
Figure 3: Percentage Distribution of Worldwide Population (Aged 65 Years and Older), by Region, 2016 and 2050
Figure 4: Household Disposable Income Across Selected Countries, 2012-2018
Figure 5: Population Aged 65 Years and Older, 2012-2017
Figure 6: Number of People with Dementia Worldwide, by Income Level, 2015-2050
Figure 7: Global Number of Adults with Diabetes, 2015 and 2040
Figure 8: Top 10 Countries with the Highest Prevalence of Diabetes, 2015
Figure 9: Percentage Distribution of Increasing Diabetes Cases, by Region, 2015-2040
Figure 10: Global Cancer Prevalence, by Type, 2016
Figure 11: Cancer Prevalence Across Regions, by Type, 2015-2016
Figure 12: Canadian Population Shares Distribution, by Province or Territory, 2018
Figure 13: Index of Mean and Median Equivalized Household Disposable Income in the U.K., 2015-2017
Figure 14: Geriatric Population in France, 2012 and 2017
Figure 15: Total Rural Income in India, 2015 and 2021
Figure 16: Share of Japanese Population Aged 65 Years and Older, 2015 and 2050
Figure 17: Share of Australian Population Aged 60 Years and Older, 2015 and 2050
Figure 18: Disposable Income in UAE, 2010 and 2017
Figure 19: Industry Structure and Process Flow: Longevity and Anti-senescence Industry
